Charlaine A Aventurado1, Junie B Billones2, Ross D Vasquez1,3,4, Agnes L Castillo1,3,4. 1. The Graduate School, University of Santo Tomas, Manila 1015, Philippines. 2. Department of Physical Sciences and Mathematics, College of Arts and Sciences, University of the Philippines Manila, Manila, Philippines. 3. Faculty of Pharmacy, University of Santo Tomas, Manila 1015, Philippines. 4. Research Center for the Natural and Applied Sciences, University of Santo Tomas, Manila 1015, Philippines.
Abstract
INTRODUCTION: Cancer is considered as one of the deadliest human diseases today. Angiogenesis, the propagation of new blood vessels from pre-existing vasculature, is a critical step in the progression of cancer as it is essential in the growth and metastasis of tumors. Hence, suppression of angiogenesis is a promising approach in cancer therapy. Syringin, a phenylpropanoid glycoside with a molecular formula of C17H24O9, has been found to exhibit chemopreventive effects. However, its anti-angiogenic activity and the underlying mechanism of action are still unknown. METHODS: In this work, in ovo chorioallantoic membrane (CAM) assay has been conducted to evaluate the effect of syringin on neovascularization. Additionally, reverse molecular docking studies have been performed in order to identify the probable enzyme targets in the angiogenesis pathway. RESULTS: Treatment with syringin showed significant dose-dependent inhibition of blood vessel length and junctions in the CAM of duck eggs; the anti-angiogenic activity of syringin at 100 µM and 200 µM is comparable with 200 µM of the positive control celecoxib. The results of reverse docking studies indicate that syringin binds the strongest to dihydrofolate reductase (DHFR) and, to some extent, with transforming growth factor-beta receptor type 1 (TGF-βR1), vascular endothelial growth factor receptor 2 (VEGFR2), and matrix metalloproteinase-2 (MMP-2). Furthermore, ADMET models revealed that syringin potentially possesses excellent pharmacokinetic and toxicity profiles. CONCLUSION: This study demonstrates the potential of syringin as an anti-angiogenic agent and elicits further investigations to establish its application in cancer suppression.
INTRODUCTION: Cancer is considered as one of the deadliest human diseases today. Angiogenesis, the propagation of new blood vessels from pre-existing vasculature, is a critical step in the progression of cancer as it is essential in the growth and metastasis of tumors. Hence, suppression of angiogenesis is a promising approach in cancer therapy. Syringin, a phenylpropanoid glycoside with a molecular formula of C17H24O9, has been found to exhibit chemopreventive effects. However, its anti-angiogenic activity and the underlying mechanism of action are still unknown. METHODS: In this work, in ovo chorioallantoic membrane (CAM) assay has been conducted to evaluate the effect of syringin on neovascularization. Additionally, reverse molecular docking studies have been performed in order to identify the probable enzyme targets in the angiogenesis pathway. RESULTS: Treatment with syringin showed significant dose-dependent inhibition of blood vessel length and junctions in the CAM of duck eggs; the anti-angiogenic activity of syringin at 100 µM and 200 µM is comparable with 200 µM of the positive control celecoxib. The results of reverse docking studies indicate that syringin binds the strongest to dihydrofolate reductase (DHFR) and, to some extent, with transforming growth factor-beta receptor type 1 (TGF-βR1), vascular endothelial growth factor receptor 2 (VEGFR2), and matrix metalloproteinase-2 (MMP-2). Furthermore, ADMET models revealed that syringin potentially possesses excellent pharmacokinetic and toxicity profiles. CONCLUSION: This study demonstrates the potential of syringin as an anti-angiogenic agent and elicits further investigations to establish its application in cancer suppression.
Authors: Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Lennart Berglin; Sylvia Sarman; Ingeborg van der Ploeg; Björn Steen; Yue Ming; Shigeyoshi Itohara; Stefan Seregard; Anders Kvanta Journal: Invest Ophthalmol Vis Sci Date: 2003-01 Impact factor: 4.799
Authors: Anna Neve; Francesco Paolo Cantatore; Nicola Maruotti; Addolorata Corrado; Domenico Ribatti Journal: Biomed Res Int Date: 2014-05-18 Impact factor: 3.411
Authors: Junie B Billones; Maria Constancia O Carrillo; Voltaire G Organo; Jamie Bernadette A Sy; Nina Abigail B Clavio; Stephani Joy Y Macalino; Inno A Emnacen; Alexandra P Lee; Paul Kenny L Ko; Gisela P Concepcion Journal: Drug Des Devel Ther Date: 2017-03-02 Impact factor: 4.162